CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope.
Skowera A, Ellis RJ, Varela-Calviño R, Arif S, Huang GC, Van-Krinks C, Zaremba A, Rackham C, Allen JS, Tree TI, Zhao M, Dayan CM, Sewell AK, Unger WW, Drijfhout JW, Ossendorp F, Roep BO, Peakman M.
Skowera A, et al. Among authors: rackham c.
J Clin Invest. 2008 Oct;118(10):3390-402. doi: 10.1172/JCI35449.
J Clin Invest. 2008.
PMID: 18802479
Free PMC article.